| Pharmaceutical Information |
| Drug Name |
Raltegravir |
| Drug ID |
BADD_D01905 |
| Description |
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. |
| Indications and Usage |
For the treatment of HIV-1 infection in conjunction with other antiretrovirals. |
| Marketing Status |
Prescription |
| ATC Code |
J05AJ01 |
| DrugBank ID |
DB06817
|
| KEGG ID |
D06676
|
| MeSH ID |
D000068898
|
| PubChem ID |
54671008
|
| TTD Drug ID |
D0I1FQ
|
| NDC Product Code |
65977-0049; 70518-1621; 17381-749; 68071-2113; 0006-3080; 0006-0477; 0006-0473; 0006-0227; 50090-1085; 0006-3603 |
| Synonyms |
Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress |
|
| Chemical Information |
| Molecular Formula |
C20H21FN6O5 |
| CAS Registry Number |
518048-05-0 |
| SMILES |
CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
